



Confirmation of HLA Typing

Registry Use Only

Sequence Number:

Date Received:

OMB No: 0915-0310
 Expiration Date: 08/31/2025

Public Burden Statement: The purpose of this data collection system is to provide technical assistance and share expertise with health care organizations, health care providers and health care networks interested in implementing telehealth technology. The resource centers serve as focal points for advancing the effective use of telehealth technologies in their respective communities and regions. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0915-0310 and it is valid until 08/31/2025. Public reporting burden for this collection of information is estimated to average 0.27 hours per response, including the time for reviewing instructions, searching existing data sources, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance Officer, 5600 Fishers Lane, Room 14N136B, Rockville, Maryland, 20857 or paperwork@hrsa.gov.

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Event date: _____
 YYYY MM DD

Product Identifiers:

Registry donor ID: _____

Non-NMDP cord blood unit ID: _____

Global Registration Identifier for Donors (GRID): _____

ISBT DIN: _____

Registry or UCB Bank ID: _____

Donor DOB: _____ - _____ - _____
 YYYY MM DD

Donor Age: ____ Months (use only if less than 1 year old)
 Years

Donor Sex: Male Female

Donor / Cord Blood Unit Identification

This form must be completed for all non-NMDP allogeneic or syngeneic donors or recipients, or non-NMDP cord blood units. If the donor, recipient, or cord blood unit was secured through the NMDP, then report HLA typing on the appropriate NMDP forms.

A separate copy of this form should be completed for each non-NMDP donor, recipient, or cord blood unit.

1. Specify the person for whom this typing is being done:

- Recipient — final typing
- Donor

HLA Typing by DNA Technology

2. Was documentation submitted to the CIBMTR? (e.g. lab report)

- Yes
- No

HLA Alleles Defined by DNA Technology (e.g., Sequence Specific Oligonucleotide Probe (SSOP) typing, Sequence Specific Primer (SSP) typing or Sequence Based (SBT) typing.)

DNA technology can be used to type for a single allele, combinations of alleles (allele strings) or a “generic” allele designation which is similar to a serologic typing result. For this reason, the number of digits, as well as the number of alleles, for reporting will vary.

Laboratories may use “ / ”, “ – ” or a combination of numbers and letters on the typing report as a shorthand notation for the results. Transcribe the information onto the form as directly as possible. The letters are called allele codes, and will be 1 or more characters in length which represent a combination of possible alleles at a locus. The same allele combination may be reported several different ways (e.g., DRB1*01:01 or 01:02, DRB1*01:01/01:02, DRB1*01:01/02, or DRB1*01:AB).

There will be two alleles reported for each locus, unless the individual is presumed homozygous (i.e., carries two copies of the same allele) at a locus. Transcribe the first allele designation in the first box, and the second allele designation in the second box. If the person is homozygous, leave the second box blank.

Class I

3. Locus A

- Known – **Go to question 4**
- Unknown – **Go to question 5**

4. First A* allele designations

--	--

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Second A* allele designations

5. Locus B

Known – **Go to question 6**

Unknown – **Go to question 7**

6. First B* allele designations

Second B* allele designations

7. Locus C

Known – **Go to question 8**

Unknown – **Go to question 9**

8. First C* allele designations

Second C* allele designations

Class II

9. Locus DRB1

Known – **Go to question 10**

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Unknown – **Go to question 11**

10. First DRB1* allele designations

Second DRB1* allele designations

Class II (Optional)

Please provide the optional allele information if it is available from your laboratory.

11. Locus DRB3

Known – **Go to question 12**

Unknown – **Go to question 13**

12. First DRB3* allele designations

Second DRB3* allele designations

13. Locus DRB4

Known – **Go to question 14**

Unknown – **Go to question 15**

14. First DRB4* allele designations

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Second DRB4* allele designations

15. Locus DRB5

Known – **Go to question 16**

Unknown – **Go to question 17**

16. First DRB5* allele designations

Second DRB5* allele designations

17. Locus DQB1

Known – **Go to question 18**

Unknown – **Go to question 19**

18. First DQB1* allele designations

Second DQB1* allele designations

19. Locus DPB1

Known – **Go to question 20**

Unknown – **Go to question 21**

20. First DPB1* allele designations

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Second DPB1* allele designations

21. Locus DQA1

Known – **Go to question 22**

Unknown – **Go to question 23**

22. First DQA1* allele designations

Second DQA1* allele designations

23. Locus DPA1

Known – **Go to question 24**

Unknown – **Go to question 25**

24. First DPA1* allele designations

Second DPA1* allele designations

Antigens Defined by Serologic Typing

CIBMTR Center Number: _____ CIBMTR Research ID: _____

Use the following lists when reporting HLA-A and B antigens. Report broad antigens only when your laboratory was not able to confirm typing for a known split antigen.

Instructions for the use of the “X” Antigen Specificity for Typing By Serology

Each HLA locus has a serologically defined “X” antigen specificity: AX, BX, CX, DRX, DPX, and DQX. At this time an “X” specificity is defined as “unknown but known to be different from the other antigen at that locus.” This is different from a blank specificity, which is defined as “unknown but assumed to be the same as the other antigen at that locus.” When comparisons between recipient and donor antigens involve an “X” or “blank” specificity, the “X” or “blank” is assumed to be homozygous for the antigen reported at the locus. In other words, the search algorithm treats typings containing “blank” or “X” antigens in the same manner as known homozygous typings.

A Antigens

25. Number of antigens provided:

- One – **Go to question 26, then continue with question 28**
- Two – **Go to questions 26-27**

26. Specificity – 1st antigen

- A1
- A2
- A203
- A210
- A3
- A9
- A10
- A11
- A19
- A23(9)
- A24(9)
- A2403
- A25(10)
- A26(10)
- A28
- A29(19)
- A30(19)
- A31(19)
- A32(19)
- A33(19)
- A34(10)
- A36
- A43
- A66(10)
- A68(28)
- A69(28)
- A74(19)
- A80
- AX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

27. Specificity – 2nd antigen

- A1
- A2
- A203
- A210
- A3
- A9
- A10
- A11
- A19
- A23(9)
- A24(9)
- A2403
- A25(10)
- A26(10)
- A28
- A29(19)
- A30(19)
- A31(19)
- A32(19)
- A33(19)
- A34(10)
- A36
- A43
- A66(10)
- A68(28)
- A69(28)
- A74(19)
- A80
- AX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

B Antigens

28. Number of antigens provided:

One – **Go to question 29, then continue with question 31**

Two – **Go to questions 29-30**

29. Specificity – 1st antigen

B5

B7

B703

B8

B12

B13

B14

B15

B16

B17

B18

B21

B22

B27

B2708

B35

B37

B38(16)

B39(16)

B3901

B3902

B40

B4005

B41

B42

B44(12)

B45(12)

B46

B47

B48

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- B49(21)
- B50(21)
- B51(5)
- B5102
- B5103
- B52(5)
- B53
- B54(22)
- B55(22)
- B56(22)
- B57(17)
- B58(17)
- B59
- B60(40)
- B61(40)
- B62(15)
- B63(15)
- B64(14)
- B65(14)
- B67
- B70
- B71(70)
- B72(70)
- B73
- B75(15)
- B76(15)
- B77(15)
- B78
- B81
- B82
- BX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

30. Specificity – 2nd antigen

- B5
- B7
- B703
- B8
- B12
- B13
- B14
- B15
- B16
- B17
- B18
- B21
- B22
- B27
- B2708
- B35
- B37
- B38(16)
- B39(16)
- B3901
- B3902
- B40
- B4005
- B41
- B42
- B44(12)
- B45(12)
- B46
- B47
- B48
- B49(21)
- B50(21)
- B51(5)
- B5102
- B5103

CIBMTR Center Number: _____

CIBMTR Research ID: _____

- B52(5)
- B53
- B54(22)
- B55(22)
- B56(22)
- B57(17)
- B58(17)
- B59
- B60(40)
- B61(40)
- B62(15)
- B63(15)
- B64(14)
- B65(14)
- B67
- B70
- B71(70)
- B72(70)
- B73
- B75(15)
- B76(15)
- B77(15)
- B78
- B81
- B82
- BX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Optional Antigen Reporting

Please provide the following optional antigen information if it is available from your laboratory.

Antigens Defined by Serologic Typing

C Antigens

31. Number of antigens provided:

- One – **Go to question 32, then continue with question 34**
- Two – **Go to questions 32-33**

32. Specificity – 1st antigen

- Cw1
- Cw2
- Cw3
- Cw4
- Cw5
- Cw6
- Cw7
- Cw8
- Cw9(w3)
- Cw10(w3)
- CX

33. Specificity – 2nd antigen

- Cw1
- Cw2
- Cw3
- Cw4
- Cw5
- Cw6
- Cw7
- Cw8
- Cw9(w3)
- Cw10(w3)
- CX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

Bw Specificity

34. Specificity Bw4 present?

Yes

No

35. Specificity Bw6 present?

Yes

No

DR Antigens

36. Number of antigens provided:

One – **Go to question 37, then continue with question 39**

Two – **Go to questions 37-38**

37. Specificity – 1st antigen

DR1

DR103

DR2

DR3

DR4

DR5

DR6

DR7

DR8

DR9

DR10

DR11(5)

DR12(5)

DR13(6)

DR14(6)

DR1403

DR1404

DR15(2)

DR16(2)

DR17(3)

DR18(3)

CIBMTR Center Number: _____

CIBMTR Research ID: _____

DRX

38. Specificity – 2nd antigen

DR1

DR103

DR2

DR3

DR4

DR5

DR6

DR7

DR8

DR9

DR10

DR11(5)

DR12(5)

DR13(6)

DR14(6)

DR1403

DR1404

DR15(2)

DR16(2)

DR17(3)

DR18(3)

DRX

DR51 Antigen

39. Specificity DR51 present?

Yes

No

CIBMTR Center Number: _____

CIBMTR Research ID: _____

DR52 Antigen

40. Specificity DR52 present?

Yes

No

DR53 Antigen

41. Specificity DR53 present?

Yes

No

DQ Antigens

42. Number of antigens provided:

One – **Go to question 43, then continue with question 45**

Two – **Go to questions 43-44**

43. Specificity – 1st antigen

DQ1

DQ2

DQ3

DQ4

DQ5(1)

DQ6(1)

DQ7(3)

DQ8(3)

DQ9(3)

DQX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

44. Specificity – 2nd antigen

- DQ1
- DQ2
- DQ3
- DQ4
- DQ5(1)
- DQ6(1)
- DQ7(3)
- DQ8(3)
- DQ9(3)
- DQX

DP Antigens

45. Number of antigens provided:

- One – **Go to question 46, then continue with signature line**
- Two – **Go to questions 46-47**

46. Specificity – 1st antigen

- DPw1
- DPw2
- DPw3
- DPw4
- DPw5
- DPw6
- DPX

47. Specificity – 2nd antigen

- DPw1
- DPw2
- DPw3
- DPw4
- DPw5
- DPw6
- DPX

CIBMTR Center Number: _____

CIBMTR Research ID: _____

First Name: _____
Person completing form

Last Name: _____

E-mail address: _____

Date: _____ - _____ - _____
 YYYY MM DD